What is Rein Therapeutics, Inc.'s earnings per share (EPS)?

Rein Therapeutics, Inc. (RNTX) reported diluted earnings per share of -$1.96 for fiscal year 2025. This represents a 44.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rein Therapeutics, Inc. (RNTX) Financials

RNTX

FY2025 annual

Revenue $0 YoY not available

Net Income -$49.9M +20.7% YoY

EPS (Diluted) -$1.96 +44.2% YoY

Operating Cash Flow -$19.4M +13.1% YoY

Market Cap $50.6M as of Oct 15, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.9x on $55.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RNTX SEC filings page.

Rein Therapeutics, Inc. (RNTX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RNTX FY2025 2026-10-03

The business remains development-led: losses narrowed, but cash use and weaker liquidity keep financing central to operations.

The FY2025 net loss of $49.9M was more than twice operating cash outflow of $19.4M, so accounting losses and cash needs are materially different. Both measures improved from FY2024, yet the cash improvement was smaller than the earnings improvement, meaning the narrower loss did not translate one-for-one into reduced cash use.

Assets fell from $62.2M in FY2024 to $24.2M in FY2025, shrinking the balance-sheet base supporting operations. The current ratio fell from 2.4x to 0.7x, indicating short-term obligations exceeded current assets; leverage also rose as equity contracted.

FY2025 financing provided $9.8M against operating cash use of $19.4M, so external funding offset only part of internal cash use. R&D and SG&A were nearly equal at $11.0M and $10.9M, showing a split spending base between program work and corporate overhead.

Financial Health Signals

Financial health score not available

Rein Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-26.07

Rein Therapeutics, Inc. scores -26.07, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($50.6M) relative to total liabilities ($7.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Rein Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Rein Therapeutics, Inc. reported a net loss of $49.9M while operations used $19.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Rein Therapeutics, Inc. generated $0 in revenue in Q2 2026.

Net Income

-$6.4M

YoY+6.6%

QoQ-9.2%

Rein Therapeutics, Inc. reported -$6.4M in net income in Q2 2026. This represents an increase of 6.6% from the same quarter a year earlier. Against the prior quarter it is down 9.2%.

EPS (Diluted)

-$0.10

Rein Therapeutics, Inc. earned -$0.10 per diluted share (EPS) in Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$8.5M

YoY+49.3%

QoQ+92.2%

5Y CAGR-4.5%

10Y CAGR+8.2%

Rein Therapeutics, Inc. held $8.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

86M

5Y CAGR-1.0%

Rein Therapeutics, Inc. had 86M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-11.6%

YoY+2.7pp

QoQ+38.8pp

Rein Therapeutics, Inc.'s ROE was -11.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 38.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$3.6M

YoY-15.2%

QoQ+18.4%

Rein Therapeutics, Inc. invested $3.6M in research and development in Q2 2026. This represents a decrease of 15.2% from the same quarter a year earlier. Against the prior quarter it is up 18.4%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

RNTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RNTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expenses	N/A	$11.0M-22.6%	$14.2M+257.0%	$4.0M-77.8%	$18.0M+5.6%	$17.0M+52.3%	$11.2M-36.8%	$17.7M-4.3%	$18.4M+29.6%	$14.2M+38.6%	$10.3M+31.2%	$7.8M
SG&A Expenses	N/A	$10.9M-21.4%	$13.9M+22.1%	$11.4M+17.3%	$9.7M+0.9%	$9.6M+2.9%	$9.3M-24.1%	$12.3M-8.6%	$13.5M+53.4%	$8.8M+11.1%	$7.9M+56.0%	$5.1M
Operating Income	N/A	-$50.6M+22.2%	-$65.1M-300.0%	-$16.3M+41.1%	-$27.6M-3.9%	-$26.6M-29.8%	-$20.5M+31.6%	-$30.0M+6.1%	-$31.9M-38.7%	-$23.0M-26.6%	-$18.2M-40.9%	-$12.9M
EBITDA	N/A	-$50.6M+22.2%	-$65.0M-302.6%	-$16.2M+41.2%	-$27.5M-3.8%	-$26.5M-30.3%	-$20.3M+31.8%	-$29.8M+5.9%	-$31.7M-38.5%	-$22.9M-27.6%	-$17.9M-42.7%	-$12.6M
Income Tax	N/A	-$712K+53.9%	-$1.5M	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$49.9M+20.7%	-$62.9M-300.6%	-$15.7M+42.6%	-$27.3M-4.5%	-$26.2M+4.3%	-$27.3M+6.9%	-$29.4M+6.9%	-$31.5M-39.6%	-$22.6M-24.7%	-$18.1M-40.7%	-$12.9M
EPS (Basic)	N/A	-$1.96+44.2%	-$3.51-2.6%	-$3.42+43.2%	-$6.02-2.2%	-$5.89	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.96+44.2%	-$3.51	-$3.42	-$6.02	-$5.89	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	25M+41.8%	18M	5M	5M	4M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0
R&D Expenses	$3.6M-15.2%	$3.1M+0.6%	N/A	$1.7M-54.8%	$4.3M+14.7%	$3.1M-11.8%	N/A	$3.7M+16818.2%
SG&A Expenses	$2.4M-5.5%	$2.2M-15.6%	N/A	$3.8M+62.2%	$2.6M-51.3%	$2.6M-31.7%	N/A	$2.3M+20.2%
Operating Income	-$6.1M+11.6%	-$5.2M+6.8%	N/A	-$5.5M+9.5%	-$6.9M+24.0%	-$5.6M+22.2%	N/A	-$6.1M-206.2%
EBITDA	N/A	N/A	N/A	-$5.5M+9.5%	-$6.9M+24.0%	-$5.6M+21.5%	N/A	-$6.1M-208.0%
Net Income	-$6.4M+6.6%	-$5.8M-6.1%	N/A	-$5.6M+4.5%	-$6.8M+23.7%	-$5.5M+22.7%	N/A	-$5.8M-220.0%
EPS (Basic)	-$0.10+64.3%	-$0.19+24.0%	-$1.22+44.5%	-$0.21+22.2%	-$0.28+37.8%	-$0.25+70.9%	-$2.20-40.1%	-$0.27+32.5%
EPS (Diluted)	-$0.10	-$0.19	-$1.22+44.5%	-$0.21+22.2%	-$0.28+37.8%	-$0.25	-$2.20-40.1%	-$0.27
Diluted Shares (Avg)	67M	30M	N/A	26M+21.7%	24M+21.5%	22M	N/A	22M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

RNTX Balance Sheet

RNTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Total Assets	$24.2M-61.2%	$62.2M-41.3%	$106.0M+381.7%	$22.0M-54.6%	$48.5M+196.7%	$16.3M-38.3%	$26.5M-12.7%	$30.3M-42.5%	$52.7M+139.3%	$22.0M	N/A
Current Assets	$4.3M-68.3%	$13.7M-25.2%	$18.3M-16.5%	$21.9M-54.6%	$48.2M+195.1%	$16.3M-16.5%	$19.6M-10.2%	$21.8M-58.0%	$51.8M+146.0%	$21.1M	N/A
Cash & Equivalents	$3.2M-75.0%	$12.9M-25.8%	$17.3M+233.8%	$5.2M+44.3%	$3.6M-48.9%	$7.0M+32.7%	$5.3M-50.1%	$10.6M-10.4%	$11.9M-42.7%	$20.7M+449.8%	$3.8M
Short-Term Investments	$0	$0	$0-100.0%	$16.0M-62.1%	$42.3M+526.3%	$6.8M-47.9%	$13.0M+28.9%	$10.1M-74.1%	$38.9M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$6.3M0.0%	$6.3M0.0%	$6.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.2M-7.2%	$7.8M+1.1%	$7.7M+127.9%	$3.4M-26.1%	$4.6M+9.5%	$4.2M-59.9%	$10.4M-2.7%	$10.7M+119.0%	$4.9M-96.3%	$133.8M	N/A
Current Liabilities	$6.2M+7.5%	$5.7M+31.1%	$4.4M+29.6%	$3.4M-24.9%	$4.5M+13.8%	$4.0M-32.2%	$5.8M+8.7%	$5.4M+9.8%	$4.9M+20.1%	$4.1M	N/A
Non-Current Liabilities	$1.1M-48.3%	$2.0M-38.4%	$3.3M	$0-100.0%	$69K-68.5%	$219K-95.2%	$4.6M-14.2%	$5.3M	$0-100.0%	$129.8M	N/A
Total Equity	$16.9M-68.9%	$54.4M-44.7%	$98.3M+427.8%	$18.6M-57.6%	$43.9M+261.0%	$12.2M-24.2%	$16.0M-18.1%	$19.6M-59.0%	$47.8M+142.7%	-$111.8M-18.5%	-$94.3M
Retained Earnings	-$401.3M-14.2%	-$351.4M-21.8%	-$288.5M-5.8%	-$272.8M-11.1%	-$245.5M-11.9%	-$219.3M-10.7%	-$198.1M-17.6%	-$168.5M-23.0%	-$136.9M-19.8%	-$114.3M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$66.0M+14.8%	$26.3M-54.4%	$24.2M-61.2%	$53.7M-48.5%	$57.5M-47.5%	$57.6M-41.9%	$62.2M-41.3%	$104.2M+712.8%
Current Assets	$41.5M+527.9%	$5.5M-34.5%	$4.3M-68.3%	$5.2M-72.3%	$6.6M-71.5%	$8.3M-34.7%	$13.7M-25.2%	$18.7M+46.0%
Cash & Equivalents	$8.5M+49.3%	$4.4M-40.2%	$3.2M-75.0%	$4.0M-77.1%	$5.7M-73.9%	$7.4M-38.3%	$12.9M-25.8%	$17.7M+46.3%
Short-Term Investments	$32.1M	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$3.0M	$0	$0	$0	$0	$0	$0	$0
Goodwill	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M0.0%	$6.3M
Total Liabilities	$10.8M+13.8%	$14.7M+89.7%	$7.2M-7.2%	$7.5M-16.3%	$9.5M+13.0%	$7.7M-1.4%	$7.8M+1.1%	$9.0M+453.3%
Current Liabilities	$9.7M+26.2%	$13.6M+128.2%	$6.2M+7.5%	$5.7M+1.5%	$7.7M+55.8%	$6.0M+31.9%	$5.7M+31.1%	$5.7M+248.5%
Non-Current Liabilities	$1.1M-40.2%	$1.1M-40.2%	$1.1M-48.3%	$1.8M-46.7%	$1.8M-48.5%	$1.8M-46.7%	$2.0M-38.4%	$3.3M
Total Equity	$55.2M+15.0%	$11.6M-76.8%	$16.9M-68.9%	$46.2M-51.5%	$48.0M-52.5%	$49.9M-45.4%	$54.4M-44.7%	$95.2M+750.4%
Retained Earnings	-$413.5M-13.7%	-$407.1M-14.1%	-$401.3M-14.2%	-$369.3M-19.0%	-$363.7M-19.4%	-$356.9M-20.7%	-$351.4M-21.8%	-$310.4M-10.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

RNTX Cash Flow Statement

RNTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Operating Cash Flow	-$18.8M	-$19.4M+13.1%	-$22.3M-12.5%	-$19.8M+20.3%	-$24.9M-4.7%	-$23.8M-16.0%	-$20.5M+22.7%	-$26.5M+5.2%	-$27.9M-36.0%	-$20.5M-36.7%	-$15.0M-28.2%	-$11.7M
Depreciation & Amortization	N/A	$1K-98.4%	$63K-47.1%	$119K-29.6%	$169K+39.7%	$121K-25.8%	$163K+5.2%	$155K-28.9%	$218K+69.0%	$129K-44.4%	$232K-28.6%	$325K
Stock-Based Compensation	N/A	$2.2M+99.1%	$1.1M-6.1%	$1.2M-42.9%	$2.1M-7.8%	$2.3M+19.4%	$1.9M-10.5%	$2.1M-35.5%	$3.3M+87.5%	$1.7M+154.2%	$688K+9.9%	$626K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$157K+3040.0%	$5K-96.7%	$151K-96.6%	$4.4M+3014.8%	$142K	N/A	$94K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$23.9M-16.7%	-$20.5M+23.1%	-$26.6M+17.7%	-$32.3M-56.5%	-$20.7M	N/A	-$11.8M
Investing Cash Flow	N/A	N/A	$0-100.0%	$16.2M-38.8%	$26.5M+173.7%	-$35.9M-660.2%	$6.4M+327.8%	-$2.8M-111.4%	$24.7M+163.4%	-$38.9M	N/A	N/A
Financing Cash Flow	$56.8M	$9.8M-45.3%	$17.8M+12.8%	$15.8M	N/A	$55.7M+252.3%	$15.8M-34.1%	$24.0M+852.8%	$2.5M-95.0%	$50.6M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$8.6M-34.6%	-$3.4M+44.6%	-$3.2M+33.1%	-$3.5M+7.1%	-$6.4M+23.5%	-$6.2M-17.2%	-$4.8M+53.7%	-$3.8M-132.9%
Depreciation & Amortization	N/A	N/A	$0	$0	$1K-75.0%	$0-100.0%	$0-100.0%	$0-100.0%
Stock-Based Compensation	$164K-35.9%	$156K-40.9%	N/A	$1.4M+184.8%	$256K-21.5%	$264K+76.0%	N/A	$508K+121.8%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0+100.0%	$0-100.0%
Financing Cash Flow	$47.8M+914.7%	$4.7M+530.6%	$2.4M+240400.0%	$1.9M+526.0%	$4.7M-74.2%	$738K	$1K-100.0%	-$446K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

RNTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RNTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K
Return on Equity	-294.9%-179.3pp	-115.6%-99.7pp	-16.0%+130.8pp	-146.8%-87.2pp	-59.6%+165.1pp	-224.7%-41.7pp	-183.0%-22.1pp	-160.9%-113.7pp	-47.3%	N/A	N/A
Return on Assets	-206.6%-105.4pp	-101.1%-86.3pp	-14.8%+109.4pp	-124.2%-70.2pp	-54.0%+113.3pp	-167.2%-56.3pp	-110.9%-6.9pp	-104.1%-61.2pp	-42.9%+39.4pp	-82.3%	N/A
Current Ratio	0.70-1.7x	2.38-1.8x	4.17-2.3x	6.46-4.2x	10.69+6.6x	4.12+0.8x	3.35-0.7x	4.05-6.5x	10.60+5.4x	5.18	N/A
Debt-to-Equity	0.43+0.3x	0.14+0.1x	0.08-0.1x	0.18+0.1x	0.10-0.2x	0.34-0.3x	0.65+0.1x	0.55+0.4x	0.10	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-11.6%+2.7pp	-50.4%-39.3pp	N/A	-12.1%-5.9pp	-14.2%-5.4pp	-11.0%-3.2pp	N/A	-6.1%+10.2pp
Return on Assets	-9.7%+2.2pp	-22.2%-12.7pp	N/A	-10.4%-4.8pp	-11.9%-3.7pp	-9.6%-2.4pp	N/A	-5.6%+8.6pp
Current Ratio	4.27+3.4x	0.40-1.0x	0.70-1.7x	0.90-2.4x	0.86-3.8x	1.39-1.4x	2.38-1.8x	3.30-4.6x
Debt-to-Equity	0.200.0x	1.27+1.1x	0.43+0.3x	0.16+0.1x	0.20+0.1x	0.16+0.1x	0.14+0.1x	0.09-0.1x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.70), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Rein Therapeutics, Inc. RNTX	FY2025	$0	-$49.9M	N/A	$50.6M	—
Akari Therapeutics plc AKTX	FY2025	N/A	-$17.3M	N/A	$16.6M	—
Neuphoria Therapeutics Inc. NEUP	FY2026	$1.2M	-$13.5M	N/A	$17.5M	48/100
Boundless Bio, Inc. BOLD	FY2025	N/A	-$58.2M	N/A	$55.2M	—
Kezar Life Sciences, Inc. KZR	FY2025	$0	-$56.0M	N/A	$53.9M	—
Tenax Therapeutics, Inc. TENX	FY2025	$0	-$52.6M	N/A	$57.4M	—

Where Rein Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Rein Therapeutics, Inc.'s annual revenue?

Rein Therapeutics, Inc. (RNTX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Rein Therapeutics, Inc. profitable?

No, Rein Therapeutics, Inc. (RNTX) reported a net income of -$49.9M in fiscal year 2025.

What is Rein Therapeutics, Inc.'s EBITDA?

Rein Therapeutics, Inc. (RNTX) had EBITDA of -$50.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rein Therapeutics, Inc.'s return on equity (ROE)?

Rein Therapeutics, Inc. (RNTX) has a return on equity of -294.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rein Therapeutics, Inc.'s operating cash flow?

Rein Therapeutics, Inc. (RNTX) recorded an outflow of $19.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Rein Therapeutics, Inc.'s total assets?

Rein Therapeutics, Inc. (RNTX) had $24.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Rein Therapeutics, Inc. spend on research and development?

Rein Therapeutics, Inc. (RNTX) invested $11.0M in research and development during fiscal year 2025.

How many shares does Rein Therapeutics, Inc. have outstanding?

Rein Therapeutics, Inc. (RNTX) had 28M shares outstanding as of fiscal year 2025.

What is Rein Therapeutics, Inc.'s current ratio?

Rein Therapeutics, Inc. (RNTX) had a current ratio of 0.70 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Rein Therapeutics, Inc.'s debt-to-equity ratio?

Rein Therapeutics, Inc. (RNTX) had a debt-to-equity ratio of 0.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rein Therapeutics, Inc.'s return on assets (ROA)?

Rein Therapeutics, Inc. (RNTX) had a return on assets of -206.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rein Therapeutics, Inc.'s P/E ratio?

Rein Therapeutics, Inc. (RNTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $50.6M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Rein Therapeutics, Inc.'s price-to-sales ratio?

Rein Therapeutics, Inc. (RNTX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $50.6M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Rein Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Rein Therapeutics, Inc. (RNTX) held $3.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $19.4M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Rein Therapeutics, Inc.'s Altman Z-Score?

Rein Therapeutics, Inc. (RNTX) has an Altman Z-Score of -26.07, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rein Therapeutics, Inc.'s Piotroski F-Score?

Rein Therapeutics, Inc. (RNTX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rein Therapeutics, Inc.'s earnings high quality?

Rein Therapeutics, Inc. (RNTX) reported a net loss of $49.9M while operations used $19.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.